Barclays Maintains Equal-Weight on Sabra Health Care REIT, Raises Price Target to $23
Barclays analyst Richard Hightower maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Equal-Weight and raises the price target from $21 to $23.
Stocks · News reference
Raymond James Upgrades Sabra Health Care REIT to Market Perform
Raymond James analyst David Rodgers upgrades Sabra Health Care REIT (NASDAQ:SBRA) from Underperform to Market Perform.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Baird Maintains Neutral on Sabra Health Care REIT, Raises Price Target to $21
Baird analyst Vikram Malhotra maintains Sabra Health Care REIT (NASDAQ:SBRA) with a Neutral and raises the price target from $20 to $21.
This Danaos Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Wall Street analysts change outlook on top names. See all rating changes, upgrades, downgrades and initiations at Benzinga's analyst ratings page.